Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.09.012Source: DataRank Database

Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Topics (20)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Rachel Reingold ORCID,Rose Parisi ORCID,Stephen W. Dusza ORCID,Sarah Noor ORCID,Jae H. Park ORCID

Live enrichment

PubMed:41109809

National Institutes of Health National Cancer Institute

Grant: P30 CA008748

National Institutes of Health

MeSH Terms

HumansHematologic NeoplasmsSkin DiseasesAntigens, CD19Immunotherapy, AdoptiveRetrospective StudiesAdolescentAdultAgedMiddle AgedFemaleMaleYoung Adult

Keywords

RaSHDermatologyAllDlbclCrsIcansCar-t